A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

Nature Biotechnology

Volumn 23, Issue 2, 2005, Pages 201-207

  Card, Graeme L ^a   Blasdel, Landy ^a,d   England, Bruce P ^a   Zhang, Chao ^a   Suzuki, Yoshihisa ^a   Gillette, Sam ^a   Fong, Daniel ^a   Ibrahim, Prabha N ^a   Artis, Dean R ^a   Bollag, Gideon ^a   Milburn, Michael V ^a,e   Kim, Sung Hou ^b   Schlessinger, Joseph ^c   Zhang, Kam Y J ^a  

^a PLEXXIKON INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DRUG PRODUCTS; ESTERS; MOLECULAR STRUCTURE; PHOSPHORUS COMPOUNDS; SCAFFOLDS; STRUCTURAL ANALYSIS; SUBSTITUTION REACTIONS; X RAY CRYSTALLOGRAPHY;

CHEMICAL SUBSTITUTION; COCRYSTALLOGRAPHY; PHOSPHODIESTERASES (PDE); SCAFFOLD-BASED DRUG DESIGN;

ENZYME INHIBITION;

ESTER; PHOSPHODIESTERASE IV INHIBITOR; PYRAZOLE DERIVATIVE;

ARTICLE; CHEMICAL INTERACTION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; MATRIX ATTACHMENT REGION; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING;

EID: 20844437061     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1059     Document Type: Article

References (35)

1. Lipinski, C.A., Lombarde, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
2. Erlanson, D.A., McDowell, R.S. & O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 47, 3463-3482 (2004).
3. Rees, D.C., Congreve, M., Murray, C.W. & Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3, 660-672 (2004).
4. Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
5. Nienaber, V.L. et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18, 1105-1108 (2000).
6. Erlanson, D.A., Wells, J.A. & Braisted, A.C. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33, 199-223 (2004).
7. Houslay, M.D. Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Semin. Cell Dev. Biol. 9, 161-167 (1998).
8. Beavo, J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748 (1995).
9. Conti, M. & Jin, S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63, 1-38 (1999).
10. Francis, S.H., Turko, I.V. & Corbin, J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65, 1-52 (2001).
11. Corbin, J.D. & Francis, S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56, 453-459 (2002).
12. Rotella, D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 1, 674-682 (2002).
13. Souness, J.E., Aldous, D. & Sargent, C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47, 127-162 (2000).
14. Mehats, C., Andersen, C.B., Filopanti, M., Jin, S.L. & Conti, M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13, 29-35 (2002).
15. Beavo, J.A. & Brunton, L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3, 710-718 (2002).
16. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol. 14, 1317-1327 (2000).
17. Conti, M. et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 278, 5493-5496 (2003).
18. Houslay, M.D. & Adams, D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18 (2003).
19. Jin, S.L. & Conti, M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc. Natl. Acad. Sci. USA 99, 7628-7633 (2002).
20. Bardelle, C. et al. Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitors. Anal. Biochem. 275, 148-155 (1999).
21. Card, G.L. et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12, 2233-2247 (2004).
22. Srinivasan, J., Cheatham, T.E., Cieplak, P., Kollman, P.A. & Case, D.A. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120, 9401-9409 (1998).
23. Case, D.A. et al. AMBER 7 (University of California, San Francisco, 2002).
24. Zhang, K.Y.J. et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell 15, 279-286 (2004).
25. Richter, W. 1,3-Cyclopentanedione and isomeric enol-lactones. IV. Some reactions of diacetic acid ethyl ester. Helv. Chim. Acta 35, 478-485 (1952).
26. Cornell, W.D. et al. A second generation force field for the simulation of proteins, nucleic acid, and organic molecules. J. Am. Chem. Soc. 117, 5179-5197 (1995).
27. Stewart, J.J.P. MOPAC Manual (United States Air Force Academy, Colorado Springs, CO, 1985).
28. Leslie, A.G. Integration of macromolecular diffraction data. Acta Crystallogr. D55, 1696-1702 (1999).
29. Evans, P.R. Data Reduction. Proceedings of CCP4 Study Weekend, On Data Collection and Processing, Daresbury, Warrington, UK, 114-122 (1993).
30. Holton, J. & Alber, T. From the cover: automated protein crystal structure determination using ELVES. Proc. Natl. Acad. Sci. USA 101, 1537-1542 (2004).
31. Xu, R.X. et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288, 1822-1825 (2000).
32. Huai, Q. et al. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11, 865-873 (2003).
33. Brünger, A.T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D54, 905-921 (1998).
34. Murshudov, G.N., Vagin, A.A., Lebedev, A., Wilson, K.S. & Dodson, E.J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr. D55, 247-255 (1999).
35. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A47, 110-119 (1991).